Catalyst Wire Dossier Catalyst Wire Dossier

Budesonide/Albuterol Metered-dose Inhaler (PT027)

budesonide-albuterol · Bond Avillion 2 Development LP
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Budesonide/Albuterol Metered-dose Inhaler (PT027), covering 2022-09-28 to 2022-09-28. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma [Phase 3]

See pricing